全文获取类型
收费全文 | 59010篇 |
免费 | 5599篇 |
国内免费 | 1987篇 |
专业分类
耳鼻咽喉 | 189篇 |
儿科学 | 2474篇 |
妇产科学 | 342篇 |
基础医学 | 4593篇 |
口腔科学 | 447篇 |
临床医学 | 6959篇 |
内科学 | 18952篇 |
皮肤病学 | 332篇 |
神经病学 | 810篇 |
特种医学 | 2391篇 |
外国民族医学 | 7篇 |
外科学 | 4991篇 |
综合类 | 11067篇 |
现状与发展 | 7篇 |
预防医学 | 2614篇 |
眼科学 | 502篇 |
药学 | 5603篇 |
48篇 | |
中国医学 | 3182篇 |
肿瘤学 | 1086篇 |
出版年
2024年 | 79篇 |
2023年 | 1062篇 |
2022年 | 1450篇 |
2021年 | 2517篇 |
2020年 | 2770篇 |
2019年 | 2452篇 |
2018年 | 2494篇 |
2017年 | 2598篇 |
2016年 | 2517篇 |
2015年 | 2567篇 |
2014年 | 4162篇 |
2013年 | 4716篇 |
2012年 | 3751篇 |
2011年 | 3900篇 |
2010年 | 3208篇 |
2009年 | 2944篇 |
2008年 | 2848篇 |
2007年 | 2871篇 |
2006年 | 2559篇 |
2005年 | 2247篇 |
2004年 | 1767篇 |
2003年 | 1480篇 |
2002年 | 1272篇 |
2001年 | 1108篇 |
2000年 | 874篇 |
1999年 | 754篇 |
1998年 | 603篇 |
1997年 | 522篇 |
1996年 | 525篇 |
1995年 | 508篇 |
1994年 | 473篇 |
1993年 | 357篇 |
1992年 | 340篇 |
1991年 | 273篇 |
1990年 | 273篇 |
1989年 | 204篇 |
1988年 | 194篇 |
1987年 | 189篇 |
1986年 | 170篇 |
1985年 | 196篇 |
1984年 | 167篇 |
1983年 | 85篇 |
1982年 | 118篇 |
1981年 | 98篇 |
1980年 | 79篇 |
1979年 | 56篇 |
1978年 | 48篇 |
1977年 | 39篇 |
1976年 | 40篇 |
1975年 | 24篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
51.
52.
53.
54.
《Journal l'Association canadienne des radiologistes》2019,70(3):226-232
In 2017, the Canadian Association of Radiologists issued a clinical practice guideline (CPG) regarding the use of gadolinium-based contrast agents (GBCAs) in patients with acute kidney injury (AKI), chronic kidney disease (CKD), or on dialysis due to mounting evidence indicating that nephrogenic systemic fibrosis (NSF) occurs with extreme rarity or not at all when using Group II GBCAs or the Group III GBCA gadoxetic acid (compared to first generation Group I linear GBCAs). One of the goals of the work group was to re-evaluate the CPG after 24 months to determine the effect of more liberal use of GBCA on reported cases of NSF in patients with AKI, CKD Stage 4 or 5 (estimated glomerular filtration rate [eGFR] < 30 mL/min/1.73 m2), or those that are dialysis-dependent. A comprehensive review of the literature was conducted by a subcommittee of the initial CPG panel between the dates of January 1, 2017-December 31, 2018 to identify new unconfounded cases of NSF linked to Group II or Group III GBCAs and an updated CPG developed. To our knowledge, when using a Group II or Group III GBCA between 2017-2018, only a single unconfounded case report of a fibrosing dermopathy has been reported in a patient who received gadobenate dimeglumine with Stage 2 CKD. No other unconfounded cases of NSF have been reported with Group II or III agents in during this timeframe. The subcommittee concluded that the main recommendations from the 2017 CPG should remain unaltered, but agreed that screening for renal disease in the outpatient setting is no longer justifiable, cost-effective or recommended. Patients on hemodialysis (HD) should, however, be identified prior to GBCA administration to arrange timely HD to optimize gadolinium clearance, although there remains no evidence that HD reduces the risk of NSF. When administering Group II or III GBCAs to patients with AKI, on dialysis or with severe CKD, informed consent relating to NSF is also no longer explicitly recommended. 相似文献
55.
56.
Yoh Sugawara Yusuke Mizuno Shinya Oku Takahisa Goto 《British journal of anaesthesia》2019,122(4):437-447
Background
A pulmonary hypertensive crisis (PHC) can be a life-threatening condition. We established a PHC model by exposing rats with monocrotaline (MCT)-induced pulmonary hypertension to acute hypoxia, and investigated the effects of vasopressin, phenylephrine, and norepinephrine on the PHC.Methods
Four weeks after MCT 60 mg kg?1 administration i.v., right ventricular systolic pressure (RVSP), systolic BP (SBP), mean BP (MBP), cardiac index (CI), and pulmonary vascular resistance index (PVRI) were measured. PHC defined as an RVSP exceeding or equal to SBP was induced by changing the fraction of inspiratory oxygen to 0.1. Rats were subsequently treated by vasopressin, phenylephrine, or norepinephrine, followed by assessment of systemic haemodynamics, isometric tension of femoral and pulmonary arteries, cardiac function, blood gas composition, and survival.Results
PHC was associated with increased RV dilatation and paradoxical septal motion. Vasopressin increased MBP [mean (standard error)] from 52.6 (3.8) to 125.0 (8.9) mm Hg and CI from 25.4 (2.3) to 40.6 (1.8) ml min?1 100 g?1 while decreasing PVRI. Vasopressin also improved RV dilatation, oxygenation, and survival in PHC. In contrast, phenylephrine increased MBP from 54.8 (2.3) to 96.8 (3.2) mm Hg without improving cardiac pump function. Norepinephrine did not alter MBP. Vasopressin contracted femoral but not pulmonary arteries, whereas phenylephrine contracted both arterial beds. Hence, improvements with vasopressin in PHC might be associated with decreased PVRI and selective systemic vasoconstriction.Conclusions
In this rat model of a PHC, vasopressin, but not phenylephrine or norepinephrine, resulted in better haemodynamic and vascular recovery. 相似文献57.
全身型幼年特发性关节炎是儿童常见的风湿性疾病之一, 肺间质病变是指以肺间质和远端气隙重构为特征, 进而导致异常气体交换的疾病。近年来, 国内外对全身型幼年特发性关节炎合并肺间质病变的报道有增多趋势。该文总结了近年来报道中全身型幼年特发性关节炎儿童合并肺间质病变的情况, 并对儿童肺间质病变的临床表现, 影像学表现, 诊断和治疗进行综述,旨在对该类疾病有更深刻的认识, 有助于肺间质病变的早期诊治。 相似文献
58.
《Vaccine》2022,40(19):2679-2695
Vaccinations are essential for preventing infectious diseases in children with chronic diseases as they have increased risk of infection from frequent use of biologics. Response to immunizations in this group is not well known.ObjectiveA systematic review was performed to evaluate three primary outcomes: efficacy; immunogenicity; and safety of vaccines in children with chronic conditions treated with biologics.MethodsThe protocol for our systematic review and meta-analysis was registered and published with PROSPERO. We searched electronic bibliographic databases for studies published from 2009 to 2019, focusing on vaccinations in children with chronic conditions treated with biologics.ResultsWe retrieved 532 records. Thirty-one full-text articles were selected, and 14 were included in the meta-analysis. No significant publication bias was found. Efficacy: limited data are available regarding the efficacy of vaccination, as most studies have focused on immunogenicity as surrogate outcome for efficacy. Immunogenicity: patients receiving anti-TNF-alpha therapy had a statistically significant risk of poor seroconversion (p = 0.028) and seroprotection by the serotype B influenza vaccine [inflammatory bowel disease (IBD) p = 0.013; juvenile idiopathic arthritis (JIA) p = 0.004]. We found adequate responses with H1N1 and H3N2 serotypes. Few studies existed for pneumococcal, hepatitis A virus, hepatitis B virus, varicella-zoster virus, Measles Mumps Rubella virus, and multiple vaccine administration. Safety: vaccine administration was not associated with serious side effects, but JIA patients on anti-TNF alpha therapy had a statistically significant risk of presenting with myalgia or arthralgia postinfluenza vaccine (p = 0.014).ConclusionsMore evidence concerning efficacy, immunogenicity, and safety of vaccinations is needed to guide physicians in the vaccine decision process for this pediatric population. 相似文献
59.